The Coronary Artery Disease (CAD) (Ischemic Heart Disease) drugs in development market research report provides comprehensive information on the therapeutics under development for Coronary Artery Disease (CAD) (Ischemic Heart Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Coronary Artery Disease (CAD) (Ischemic Heart Disease). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) and features dormant and discontinued products.
GlobalData tracks 66 drugs in development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) by 55 companies/universities/institutes. The top development phase for Coronary Artery Disease (CAD) (Ischemic Heart Disease) is preclinical with 20 drugs in that stage. The Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline has 62 drugs in development by companies and four by universities/ institutes. Some of the companies in the Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline products market are: advanceCor, Hyloris Pharmaceuticals and MD Healthcare.
The key targets in the Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline products market include Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF), Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3), and Integrin Alpha 2b (GPalpha IIb or Platelet Membrane Glycoprotein IIb or CD41 or ITGA2B).
The key mechanisms of action in the Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline product include Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) Activator with three drugs in Phase I. The Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline products include 12 routes of administration with the top ROA being Oral and 11 key molecule types in the Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline products market including Small Molecule, and Cell Therapy.
Coronary Artery Disease (CAD) (Ischemic Heart Disease) overview
Coronary artery disease (CAD) is the most common type of heart disease. CAD happens when the arteries that supply blood to heart muscle become hardened and narrowed. This is due to the buildup of cholesterol and other material, called plaque, on their inner walls. This buildup is called atherosclerosis. As it grows, less blood can flow through the arteries. As a result, the heart muscle can’t get the blood or oxygen it needs. This can lead to chest pain (angina) or a heart attack. Most heart attacks happen when a blood clot suddenly cuts off the heart’s blood supply, causing permanent heart damage. The most common symptom of coronary artery disease is angina, or chest pain. Other symptoms include shortness of breath, palpitations, a faster heartbeat, weakness or dizziness, nausea, and sweating.
For a complete picture of Coronary Artery Disease (CAD) (Ischemic Heart Disease)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
